search
Back to results

Use of AAM for Correction of Age Related Volume Deficits in the Face

Primary Purpose

Age-Related Atrophy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AAM
Sponsored by
Musculoskeletal Transplant Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Age-Related Atrophy

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Men or women, 30-70 years of age
  2. Has overall mid-facial volume deficit of Grade 3 or 4 on Medicis Midface Volume Scale (MMVS)
  3. Willingness and ability to provide written informed consent
  4. Has not had AAM injected above the neck
  5. Ability to understand and comply with the requirements of the study
  6. Negative urine pregnancy test results at the time of study entry (if applicable).
  7. Willingness to stay on consistent and current skin care regimen for the duration of the study
  8. Willingness to maintain consistent and current diet and exercise for the duration of the study
  9. Willingness to forego any cosmetic augmentation procedure for the duration of the study
  10. Willingness to be photographed for educational, medical publication and other non-commercial purposes
  11. Has BMI ≥18 and ≤30

Exclusion Criteria:

  1. A subject with any uncontrolled systemic disease.
  2. A subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
  3. A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  4. Women that are pregnant, nursing, or planning a pregnancy during the duration of the study
  5. A subject that has had AAM injected above the neck
  6. A subject unwilling to be photographed for educational, medical publication and other non-commercial purposes
  7. A subject with a history of diabetes
  8. A subject with known hypersensitivity to any of the components of AAM
  9. A subject that has had, or who knowingly will have, dental work +/- 4 weeks prior to, or following AAM injection
  10. A subject using any systemic corticosteroid or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment and throughout the study
  11. A subject that has participated in another research study within 30 days of enrollment in this study
  12. A subject that is unwilling to forego any cosmetic augmentation treatment for the duration of the study
  13. A subject that has been treated with Botulinum Toxin below the orbital rim within 6 months of study entry.
  14. A subject that is unwilling to forego cosmetic facial treatments for the duration of the study
  15. A subject that has received Sculptra in the treatment area
  16. A subject that has received dermal filler in the treatment area within 2 years prior to randomization
  17. A subject that has previously undergone mid-face cosmetic plastic surgery, tissue grafting, or tissue augmentation with silicone, semi-permanent fillers or fat
  18. A subject that has previously undergone laser resurfacing, intense pulsed light treatment, chemical peel, or other ablative or non-ablative treatment within 6 months
  19. Subject is immunocompromised or immunosuppressed
  20. History of keloid formation or hypertrophic scars
  21. NSAID or Aspirin, other than a stable low dose aspirin regimen, within 1 week (7 days) prior to treatment
  22. Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders
  23. A subject with recent excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing)
  24. A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration)
  25. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
  26. A subject not deemed to be enrolled at the discretion of the surgeon investigator

Sites / Locations

  • Aesthetic Eyelid Plastic Surgery
  • Tennessee Clinical Research Center
  • Dallas Plastic Surgery Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Allograft Adipose Matrix (AAM) 1.0

Allograft Adipose Matrix (AAM) Diluted

Arm Description

Outcomes

Primary Outcome Measures

Volume change for the treated areas using the validated 4 point MEDICIS Mid-Face Volume Scale Assessment (MMVSA) at 24 weeks post-treatment compared to pre-treatment
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Three-D facial photography (Canfield) with computation of volume changes at 24 weeks compared to pre-treatment.

Secondary Outcome Measures

Duration of effectiveness when the average of the Evaluating Investigators' live assessments of the MMVSA scale will return to, or be worse than, the pre-treatment level over 24 weeks post-treatment.
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Volume change assessments using the Global Aesthetic Improvement Scale (GAIS) at 24 weeks post-treatment compared to pre-treatment
GAIS rates improvement in appearance. Scores range from 0 (worse) to 4 (very much improved). Higher values represent a better outcome.

Full Information

First Posted
August 28, 2018
Last Updated
May 7, 2021
Sponsor
Musculoskeletal Transplant Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT03652844
Brief Title
Use of AAM for Correction of Age Related Volume Deficits in the Face
Official Title
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
August 27, 2018 (Actual)
Primary Completion Date
July 12, 2019 (Actual)
Study Completion Date
July 12, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Musculoskeletal Transplant Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate Allograft Adipose Matrix (AAM) in the face of people with age-related volume deficit - fat loss. AAM is a tissue used to correct fat loss. Participation in this study requires injections for placing AAM in the bilateral pre-jowl and malar areas of the face. The research will tell whether AAM is effective in maintaining mid-face fullness and whether the appearance of the skin improves after injection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Atrophy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized cohorts
Masking
Participant
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Allograft Adipose Matrix (AAM) 1.0
Arm Type
Active Comparator
Arm Title
Allograft Adipose Matrix (AAM) Diluted
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
AAM
Intervention Description
Subcutaneous injection procedure
Primary Outcome Measure Information:
Title
Volume change for the treated areas using the validated 4 point MEDICIS Mid-Face Volume Scale Assessment (MMVSA) at 24 weeks post-treatment compared to pre-treatment
Description
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Time Frame
24 weeks
Title
Three-D facial photography (Canfield) with computation of volume changes at 24 weeks compared to pre-treatment.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Duration of effectiveness when the average of the Evaluating Investigators' live assessments of the MMVSA scale will return to, or be worse than, the pre-treatment level over 24 weeks post-treatment.
Description
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Time Frame
24 weeks
Title
Volume change assessments using the Global Aesthetic Improvement Scale (GAIS) at 24 weeks post-treatment compared to pre-treatment
Description
GAIS rates improvement in appearance. Scores range from 0 (worse) to 4 (very much improved). Higher values represent a better outcome.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men or women, 30-70 years of age Has overall mid-facial volume deficit of Grade 3 or 4 on Medicis Midface Volume Scale (MMVS) Willingness and ability to provide written informed consent Has not had AAM injected above the neck Ability to understand and comply with the requirements of the study Negative urine pregnancy test results at the time of study entry (if applicable). Willingness to stay on consistent and current skin care regimen for the duration of the study Willingness to maintain consistent and current diet and exercise for the duration of the study Willingness to forego any cosmetic augmentation procedure for the duration of the study Willingness to be photographed for educational, medical publication and other non-commercial purposes Has BMI ≥18 and ≤30 Exclusion Criteria: A subject with any uncontrolled systemic disease. A subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study. A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study. Women that are pregnant, nursing, or planning a pregnancy during the duration of the study A subject that has had AAM injected above the neck A subject unwilling to be photographed for educational, medical publication and other non-commercial purposes A subject with a history of diabetes A subject with known hypersensitivity to any of the components of AAM A subject that has had, or who knowingly will have, dental work +/- 4 weeks prior to, or following AAM injection A subject using any systemic corticosteroid or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment and throughout the study A subject that has participated in another research study within 30 days of enrollment in this study A subject that is unwilling to forego any cosmetic augmentation treatment for the duration of the study A subject that has been treated with Botulinum Toxin below the orbital rim within 6 months of study entry. A subject that is unwilling to forego cosmetic facial treatments for the duration of the study A subject that has received Sculptra in the treatment area A subject that has received dermal filler in the treatment area within 2 years prior to randomization A subject that has previously undergone mid-face cosmetic plastic surgery, tissue grafting, or tissue augmentation with silicone, semi-permanent fillers or fat A subject that has previously undergone laser resurfacing, intense pulsed light treatment, chemical peel, or other ablative or non-ablative treatment within 6 months Subject is immunocompromised or immunosuppressed History of keloid formation or hypertrophic scars NSAID or Aspirin, other than a stable low dose aspirin regimen, within 1 week (7 days) prior to treatment Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders A subject with recent excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration) Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study A subject not deemed to be enrolled at the discretion of the surgeon investigator
Facility Information:
Facility Name
Aesthetic Eyelid Plastic Surgery
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33431
Country
United States
Facility Name
Tennessee Clinical Research Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37215
Country
United States
Facility Name
Dallas Plastic Surgery Institute
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Use of AAM for Correction of Age Related Volume Deficits in the Face

We'll reach out to this number within 24 hrs